Real-world effectiveness and safety of lebrikizumab in adults with moderate-to-severe atopic dermatitis: a retrospective observational study with focus on head and neck involvement
Dermatology Reports · 30.07.2026
DOI: 10.4081/dr.2026.10460 ↗Kurz gefasst
Fachartikel in der Zeitschrift Dermatology Reports, online erschienen am 30.07.2026. Verfasst von Edoardo Mortato und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Systems Medicine, University of Rome "Tor Vergata". Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Lebrikizumab, an anti-interleukin (IL)-13 monoclonal antibody, is a promising treatment for moderate-to-severe atopic dermatitis (AD). We conducted a single-center, retrospective study in 21 adults with moderate-to-severe AD who were biologic-naïve and had failed or were intolerant to conventional systemic therapies. Patients received lebrikizumab 500 mg at weeks 0 and 2, then 250 mg every 2 weeks; those achieving complete remission at week 16 transitioned to monthly dosing. Assessments at baseline, weeks 6, 16, and 24 showed significant improvement in Eczema Area and Severity Index (EASI), pruritus and sleep Numeric Rating Scale (NRS), and Dermatology Life Quality Index (DLQI) scores (all p
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Systems Medicine, University of Rome "Tor Vergata".
- Dermatology Unit, Fondazione Policlinico "Tor Vergata", Rome.
- Department of Systems Medicine, University of Rome "Tor Vergata"; Dermatology Unit, Fondazione Policlinico "Tor Vergata", Rome.
Zitieren
APA
Mortato, E., Paganini, C., Talamonti, M., Maffei, V., Belcastro, A., Di Raimondo, C., Tofani, L., Bianchi, L., & Galluzzo, M. (2026). Real-world effectiveness and safety of lebrikizumab in adults with moderate-to-severe atopic dermatitis: a retrospective observational study with focus on head and neck involvement. Dermatology Reports. https://doi.org/10.4081/dr.2026.10460
Vancouver
Mortato E, Paganini C, Talamonti M, Maffei V, Belcastro A, Di Raimondo C, et al. Real-world effectiveness and safety of lebrikizumab in adults with moderate-to-severe atopic dermatitis: a retrospective observational study with focus on head and neck involvement. Dermatology Reports. 2026. doi:10.4081/dr.2026.10460
BibTeX
@article{Mortato2026,
author = {Mortato, Edoardo and Paganini, Claudia and Talamonti, Marina and Maffei, Virginia and Belcastro, Alfredo and Di Raimondo, Cosimo and Tofani, Lorenzo and Bianchi, Luca and Galluzzo, Marco},
title = {Real-world effectiveness and safety of lebrikizumab in adults with moderate-to-severe atopic dermatitis: a retrospective observational study with focus on head and neck involvement},
journal = {Dermatology Reports},
year = {2026},
doi = {10.4081/dr.2026.10460}
}
EUVIMED